Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist

[1]  Lawrence D. True,et al.  The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of D , 2014, Archives of pathology & laboratory medicine.

[2]  R. Montironi,et al.  Contemporary update on pathology-related issues on routine workup of prostate biopsy: sectioning, tumor extent measurement, specimen orientation, and immunohistochemistry. , 2014, Analytical and quantitative cytopathology and histopathology.

[3]  L. Schultz,et al.  Discontinuous Foci of Cancer in a Single Core of Prostatic Biopsy: When it Occurs and Performance of Quantification Methods in a Private-practice Setting , 2013, The American journal of surgical pathology.

[4]  M. Roobol,et al.  Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. , 2013, European urology.

[5]  M. Cooperberg,et al.  Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy , 2012, Clinical Cancer Research.

[6]  F. Montorsi,et al.  Extent of cancer of less than 50% in any prostate needle biopsy core: how many millimeters are there? , 2012, European urology.

[7]  B. Trock,et al.  Should Intervening Benign Tissue Be Included in the Measurement of Discontinuous Foci of Cancer on Prostate Needle Biopsy? Correlation With Radical Prostatectomy Findings , 2011, The American journal of surgical pathology.

[8]  A. Billis.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience , 2011 .

[9]  Thomas Wiegel,et al.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.

[10]  Matthew R Cooperberg,et al.  Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Epstein.  An update of the Gleason grading system. , 2010, The Journal of urology.

[12]  Alexandre Mamedov,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Soonmyung Paik,et al.  Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.

[14]  Dirk F Moore,et al.  Outcomes of localized prostate cancer following conservative management. , 2009, JAMA.

[15]  Andrew J Vickers,et al.  Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Humphrey,et al.  Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue , 2008, Histopathology.

[17]  Donald E Bailey,et al.  Active surveillance for early‐stage prostate cancer , 2008, Cancer.

[18]  A. D'Amico,et al.  Guideline for the management of clinically localized prostate cancer: 2007 update. , 2007, The Journal of urology.

[19]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[20]  P. Carroll,et al.  20-year outcomes following conservative management of clinically localized prostate cancer , 2005 .

[21]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[22]  Paul W Dickman,et al.  Natural history of early, localized prostate cancer. , 2004, JAMA.

[23]  M. Cooperberg,et al.  The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. , 2004, The Journal of urology.

[24]  Jerry Sullivan,et al.  Review of current literature , 1931, International Urogynecology Journal.

[25]  P. Walsh,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2003, The Journal of urology.

[26]  J A Hanley,et al.  Screening for prostate cancer: estimating the magnitude of overdetection. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.